Preparation and Characterization of Solid Lipid Nanoparticles Containing Cloricromene

REFERENCES

• J. Muller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., zur Muhlen, A., Weyhers, H., Freitas, C., and Ruhl, D. 1995. Solid lipid nanoparticles (SLN)—An alternative carrier system for controlled drug delivery. Eur.Pharm. Biopharm. 41(1):62–69.
   Google Scholar
• Muller, R. H., Mader, K., and Gohla, S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Biopharm. 50:161–177.
   PubMed Web of Science ®Google Scholar
• Mehnert, W., and Mader, K. 2001. Solid lipid nanoparticles. Produc- tion, characterization and applications. Adv. Drug Del. Rev. 47:165– 196.
   Web of Science ®Google Scholar
• Heiati, H., Tawashi, R., and Phillips, N. C. 1998. Solid lipid nanoparticles as drug carriers. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3t-azido-3tdeoxythymidine palmitate in mice. Int. J. Pharm. 174:71–80.
   Web of Science ®Google Scholar
• Yang, S., Lu, F. L., Cai, Y., Zhu, J., Liang, B. W., and Yang, C. Z. 1999. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Rel. 59:299– 307.
   Web of Science ®Google Scholar
• Cavalli, R., Caputo, O., and Gasco, M. R. 2000. Preparation and character- ization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10:305–309.
   PubMed Web of Science ®Google Scholar
• Yang, S., Zhu, J., Lu, Y., Liang, B., and Yang, C. 1999. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16:751–757.
   PubMed Web of Science ®Google Scholar
• Muller, R. H., and Runge, S. A. 1998. Solid lipid nanoparticles (SLNQR) for controlled drug delivery. In Submicron Emulsions in Drug Targeting and Delivery, ed. S. Benita, 219–234. Amsterdam: Harwood Academic.
   Google Scholar
• Muller, R. H., and Lucks, J. S. 1996. Arzneistofftrager aus festen Lipidteilchen, Feste Lipidnanospharen (SLN). Eur. Patent No. 0605497.
   Google Scholar
• Muller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., zur Muhlen, A., Weyhers, H., Freitas, C., and Ruhl, D. 1995. Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug deliv- ery. Eur. Pharm. Biopharm. 41:62–69.
   Web of Science ®Google Scholar
• zur Muhlen, A., and Mehnert, W. 1998. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53:552–555.
   Web of Science ®Google Scholar
• zur Muhlen, A., Schwarz, C., and Mehnert, W. 1998. Solid lipid nanoparti- cles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45:149–155.
   PubMed Web of Science ®Google Scholar
• Gasco, M. R. 1993. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent No. 5250236.
   Google Scholar
• Gasco, M. R. 1997. Solid lipid nanospheres from warm microemulsions. Pharm. Technol. Eur. 9:52–58.
   Google Scholar
• Sturniolo, R., Squadrito, F., Altavilla, D., Trimarchi, G. R., Prosdocimi, M., and Caputi, A. P. 1989. Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats. Circ. Shock 28:267–277.
   PubMedGoogle Scholar
• Sturniolo, R., Squadrito, F., Campo, G. M., Vinci, R., Calatroni, A., Pros- docimi, M., and Caputi, A. P. 1991. Protective effect of cloricromene, a coumarine derivative, in hypovolemic haemorrhagic shock in the rat. J. Cardiovasc. Pharmacol. 17:261–266.
   Google Scholar
• Squadrito, F., Altavilla, D., Campo, G. M., Calapai, G., Ioculano, M., Zingarelli, B., Saitta, A., Prosdocimi, M., and Caputi, A. P. 1992. Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats. Eur. J. Pharmacol. 210:107–113.
   Google Scholar
• Bertocchi, F., Breviario, F., Proserpio, P., Wang, J. M., Grezzi, P., Travagli, R. A., Prosdocimi, M., and Decana, E. 1989. In vitro inhibition of human polymorphonuclear cell function by cloricromene. Naunyn-Schmiedeberg’s Arch. Pharmacol. 339:697–703.
   Google Scholar
• Calapai, G., Squadrito, F., Rizzo, A., Marciano, M. C., Campo, G. M., and Caputi, A. P. 1995. Multiple actions of the coumarine derivative cloricromene and its protective effects on ischemic brain injury. Naunyn- Schmiedeberg’s Arch. Pharmacol. 351:209–215.
   PubMed Web of Science ®Google Scholar
• Gresele, P., Ribaldi, E., Mezzasoma, A. M., Quero, E., Stasi, M., Prosdocimi, M., Goracci, G., and Nenci, G. G. 1993. Cloricromene inhibits leukotriene formation by human polymorphonuclear leucocytes by suppressing arachidonate release from membrane phospholipids. Biochem. Pharm. 45:123– 130.
   Google Scholar
• Lidbury, P. S., Cirillo, R., and Vane, J. 1993. Dissociation of the anti- ischaemic effects of cloricromene from its anti-platelet activity. Br. J. Phar- macol. 110:275–280.
   PubMed Web of Science ®Google Scholar
• Kreuter, J. 1994. Nanoparticles. In Colloidal Drugs Delivery Systems, ed. J. Kreuter, 219–342. New York: Marcell Dekker.
   Google Scholar
• Douglas, S. J., Illum, L., and Davis, S. S. 1985. Particle size and size dis- tribution of poly(butyl-2-cyanoacrylate) nanoparticles. J. Colloid. Interface Sci. 103:154.
   Web of Science ®Google Scholar
• Lenaerts, V., Raymond, P., Juhasz, J., Simard, M. A., and Jolicoeur, C. 1989. New method for the preparation of cyanoacrylic nanoparticles with improved colloidal properties. J. Pharm. Sci. 78(12):1051–1052.
   PubMed Web of Science ®Google Scholar